Vesedaganat: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• YAP 0
• HIF-1 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

56+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth

  Northwestern University· Chicago, Egyesült Államok· 99 022 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R50

  Research specialist award to support PDIGREE (A031704) and implementation of NCI supported clinical trials at Simmons Comprehensive Cancer Center

  Ut Southwestern Medical Center· Dallas, Egyesült Államok· 164 513 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors

  Rise Therapeutics, Llc· Rockville, Egyesült Államok· 740 140 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R01

  Fasting mimicking diet and cancer stem cells in Wilms tumor

  Children's Hospital of Los Angeles· Los Angeles, Egyesült Államok· 739 756 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Southern Community Cohort Study

  Vanderbilt University Medical Center· Nashville, Egyesült Államok· 1 249 181 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finnország· EU contribution 226 277 EUR· until 2027. szept.

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Olaszország· EU contribution 1 500 000 EUR· until 2029. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 2 496 625 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, Franciaország· EU contribution 5 577 694 EUR· until 2028. ápr.· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 5 906 596 EUR· until 2027. márc.· 7 countries

10 of 245 running projects, newest first. Listed amounts together: 130,4 M USD + 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Frissítve: 2026. okt. 20.

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

  NCT04902040· M.D. Anderson Cancer Center· Frissítve: 2026. ápr. 30.

  “PI requested.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Frissítve: 2026. jan. 12.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

  NCT03829501· Kymab Limited· Frissítve: 2025. ápr. 2.

  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

  NCT03024437· Roberto Pili· Frissítve: 2025. márc. 20.

  “Genentech has closed the study due to lack of data with Atezo”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of INCB086550 in Select Solid Tumors

  NCT04629339· Incyte Corporation· Frissítve: 2025. márc. 13.

  “Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Inhibrx Biosciences, Inc· Frissítve: 2024. okt. 23.

  “Program terminated due to lack of meaningful efficacy signal.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Merck Sharp & Dohme LLC· Forrás

• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Merck Sharp & Dohme LLC· Forrás

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Arcus Biosciences, Inc.· Forrás

• A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

  NCT05468697· Merck Sharp & Dohme LLC· Forrás

• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Forrás

• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Merck Sharp & Dohme LLC· Forrás

• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Merck Sharp & Dohme LLC· Forrás

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

  NCT05899049· Merck Sharp & Dohme LLC· Forrás

• A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431· Merck Sharp & Dohme LLC· Forrás

• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

  NCT05239728· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Molecular underpinnings of metastatic small renal masses.

  JCI Insight, 2026. szept.

• Mass Spectrometry-Based Profiling of Personalized Immunopeptidomes in Thai Renal Cell Carcinoma.

  J Proteome Res, 2026. szept.

• [Driver gene mutations predicted by pathology-foundation-model and their clinical associations in clear cell renal cell carcinoma].

  Zhonghua Bing Li Xue Za Zhi, 2026. máj.

• Integrated clinicopathological, genomic, and immunophenotypic landscape of renal tubulocystic oncocytoma.

  Front Immunol, 2026. ápr.

• Subtyping atypical eosinophilic renal cell tumours through integrated morphological, immunohistochemical, and mutational characters.

  BMC Cancer, 2026. márc.

• Integrated genetic and clinical investigation of autosomal dominant hereditary uterine leiomyomas: genotype-phenotype correlation in a pakistani family.

  Mol Biol Rep, 2026. febr.

• Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.

  APMIS, 2026. jan.

• Assessing the Mutational Consequences of Chronic Arsenic Exposure Using Patient-Derived Tumor Samples and In Vitro Systems.

  Environ Mol Mutagen, 2026. jan.

• Integrating whole-exome sequencing and scRNA-seq reveal the characteristic in one clear cell renal cell carcinoma sample arising in the setting of VHL disease.

  Sci Rep, 2025. dec.

• Conventional FLCN-mutated tumor: a retrospective study of 5 cases with emphasis on diagnostic challenges.

  Hum Pathol, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.